Magenta Therapeutics Stock price

Equities

MGTA

US55910K1088

Delayed Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
30 USD -1.96% Intraday chart for Magenta Therapeutics +7.37% +168.01%
Sales 2021 - Sales 2022 - Capitalization 23.75M
Net income 2021 -71M Net income 2022 -76M EV / Sales 2021 -
Net cash position 2021 177M Net cash position 2022 82.08M EV / Sales 2022 -
P/E ratio 2021
-3.42 x
P/E ratio 2022
-0.31 x
Employees 67
Yield 2021 *
-
Yield 2022
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.96%
Current month+168.01%
Current year+168.01%
More quotes
1 year
9.07
Extreme 9.072
31.13
3 years
5.14
Extreme 5.136
227.20
5 years
5.14
Extreme 5.136
294.40
10 years
5.14
Extreme 5.136
336.00
More quotes
Date Price Change Volume
24-03-28 30 -1.96% 227,036
24-03-27 30.6 -2.92% 77,360
24-03-26 31.52 +1.71% 403,183
24-03-25 30.99 -2.97% 164,346
24-03-22 31.94 +14.32% 300,158

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
Magenta Therapeutics, Inc. is a biotechnology company focused on improving stem cell transplantation. The Company is developing medicines designed to bring the curative power of stem cell transplants to more patients with blood cancers, genetic diseases, and autoimmune diseases. Its drug development pipeline includes multiple product candidates designed to improve stem cell transplants. Its lead clinical program is designed to mobilize and collect sufficient functional stem cells for use in stem cell transplantation, a process known as mobilization. It is also developing product candidates that are designed to deplete targeted cells in the bone marrow to make space for the bone marrow to receive newly transplanted stem cells, a process known as conditioning. Its pipeline of stem cell transplant product candidates consists of MGTA-117, MGTA-145, CD45-ADC, and its research platform. The MGTA-117 program is designed to selectively deplete stem cells from patients prior to transplant.
Sector
-
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
  1. Stock
  2. Equities
  3. Stock Magenta Therapeutics - Nasdaq